<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Aesthetics</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Hair loss drugmaker Veradermics floats upsized $256M US IPO</title>
      <description>
        <![CDATA[Veradermics Inc. raised $256.3 million from an IPO on the New York Stock Exchange Feb. 4. The proceeds will fund three ongoing phase II/III clinical trials of VDPHL-01, its novel oral formulation of Rogaine (minoxidil) to treat pattern hair loss in men and women.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728557</guid>
      <pubDate>Wed, 04 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728557-hair-loss-drugmaker-veradermics-floats-upsized-256m-us-ipo</link>
    </item>
    <item>
      <title>Tensive Regenera bio-absorbable breast implant helps cancer patients</title>
      <description>
        <![CDATA[Tensive Srl's Regenera, a bio-absorbable breast implant, promises to help the millions of women who undergo breast cancer surgery every year, to feel whole again. “While surgery will save many lives, it comes at the cost of losing something very personal, which is the sense of a woman's wholeness. I think that's what has been a major challenge,” Sanjay Kakkar, CEO told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723747</guid>
      <pubDate>Fri, 12 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723747-tensive-regenera-bio-absorbable-breast-implant-helps-cancer-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Tensive-Regenera-12sept25.webp?t=1757712321" type="image/jpeg" medium="image" fileSize="366405">
        <media:title type="plain">Tensive Regenera</media:title>
        <media:description type="plain">Tensive Regenera bio-absorbable breast implant. Credit: Tensive s.r.l.</media:description>
      </media:content>
    </item>
    <item>
      <title>Imbalance seen in skin substitute use for Medicare beneficiaries</title>
      <description>
        <![CDATA[The U.S. Office of Inspector General posted an analysis of Medicare spending on skin substitutes, remarking that the data suggest a disproportionate use of these products for patients enrolled in fee-for-service (FFS) care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723704</guid>
      <pubDate>Mon, 08 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723704-imbalance-seen-in-skin-substitute-use-for-medicare-beneficiaries</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Belle.ai patents AI platform for evaluating, tracking skin conditions</title>
      <description>
        <![CDATA[A little over two months after the granting of its very first patent which described computer-based systems for diagnosing psoriasis, Belletorus Corp. welcomed the publication of two continuation-in-part child filings on similar such systems for the diagnosis of eczema and determining the severity of skin diseases such as psoriasis, eczema and skin cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708733</guid>
      <pubDate>Wed, 29 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708733-belleai-patents-ai-platform-for-evaluating-tracking-skin-conditions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/belle-ai-skin-29may24.webp?t=1717021433" type="image/jpeg" medium="image" fileSize="153918">
        <media:title type="plain">belle ai skin</media:title>
        <media:description type="plain">US20240135533-A1, “Compute system with eczema diagnostic mechanism and method of operation thereof.”Assignee: Belletorus CorporationInventors: Nguyen, Tien Dung; Nguyen, Thi Thu Hang; Fricker, Paul; Gazeau, Léa Mathilde; Gloss, Matthew Gregory; Hustache-Marmou, Thomas; Mariwalla, Kavita; McAnelly, Emily Kathryn; Morbitzer, Megan M.; Nguyen, Duong Thuy; Nguyen, Hoang-Phuong; Nguyen, Nga Thi Thuy; Nguyen, Thang Duc; Perlis, Clifford; Szajna, Christopher C.; Wolfe, JonathanIPC codes: G06T 7/00; G06T 7/136Publication date: Apr. 24, 2024Earliest priority details: US2022893632, Aug. 23, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA reports 59 deaths across the globe due to lymphoma associated with breast implants</title>
      <description>
        <![CDATA[The U.S. FDA has updated its data on the number of fatalities across globe associated with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), which has now reach 59 fatalities. That number is up from 33 reported in July 2019 but is also a number the agency continues to assert may be a significant undercount.]]>
      </description>
      <guid>http://www.bioworld.com/articles/521408</guid>
      <pubDate>Mon, 08 Aug 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/521408-fda-reports-59-deaths-across-the-globe-due-to-lymphoma-associated-with-breast-implants</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Aesthetic/breast-implant-aesthetic.webp?t=1588878559" type="image/png" medium="image" fileSize="435264">
        <media:title type="plain">Breast implants</media:title>
      </media:content>
    </item>
    <item>
      <title>Sihuan acquires majority stake in Shenzhen Yimei Medical for optoelectronics</title>
      <description>
        <![CDATA[Sihuan Pharmaceutical Holdings Group Ltd.’s subsidiary Beijing Meiyan Kongjian Biology Medicine Co. Ltd. has acquired an 80% equity stake in Shenzhen Yimei Medical Technology Co. The deal is to be completed via a mix of capital and equity transfers. Sihuan Pharmaceutical is interested in Shenzhen Yimei’s two-in-one patented technology of collimated ultrasound and superficial focused ultrasound.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517139</guid>
      <pubDate>Mon, 21 Mar 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517139-sihuan-acquires-majority-stake-in-shenzhen-yimei-medical-for-optoelectronics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/china-map.webp?t=1588615782" type="image/png" medium="image" fileSize="26836">
        <media:title type="plain">Map of China</media:title>
      </media:content>
    </item>
    <item>
      <title>Sihuan awarded medical device registration for skin repair products by NMPA</title>
      <description>
        <![CDATA[China’s NMPA has given 10 of Sihuan Pharmaceutical Holdings Group Ltd.’s skin repair products medical device registration certificates. The products are developed by its medical aesthetics platform Beijing Meiyan Kongjian Biology Medicine Co. Ltd. The certification is for three scar repair products, four medical dressing and patch products, as well as three skin repair products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517096</guid>
      <pubDate>Fri, 18 Mar 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517096-sihuan-awarded-medical-device-registration-for-skin-repair-products-by-nmpa</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-flag-regulatory.webp?t=1683139499" type="image/jpeg" medium="image" fileSize="141658">
        <media:title type="plain">Chinese flag on flagpole</media:title>
      </media:content>
    </item>
    <item>
      <title>Sihuan awarded medical device registration for skin repair products by NMPA</title>
      <description>
        <![CDATA[China’s NMPA has given 10 of Sihuan Pharmaceutical Holdings Group Ltd.’s skin repair products medical device registration certificates. The products are developed by its medical aesthetics platform, Beijing Meiyan Kongjian Biology Medicine Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516680</guid>
      <pubDate>Fri, 04 Mar 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516680-sihuan-awarded-medical-device-registration-for-skin-repair-products-by-nmpa</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/dermatologic-skin-layer-regenerative.webp?t=1745258161" type="image/jpeg" medium="image" fileSize="334698">
        <media:title type="plain">Skin, tissue layer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Collplant taps Cellink to explore regenerative breast implant production </title>
      <description>
        <![CDATA[Collplant Biotechnologies Ltd. has signed a collaboration agreement with 3D bioprinting company Cellink AB for future commercial production of regenerative breast implants. Rehovot, Israel-based Collplant has developed prototypes of 3D bioprinted implants and is evaluating them in preclinical studies. The regenerative implants are designed to degrade over time and be replaced by new, naturally grown breast tissue. The technology aims to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516139</guid>
      <pubDate>Wed, 16 Feb 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516139-collplant-taps-cellink-to-explore-regenerative-breast-implant-production</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
    <item>
      <title>Viveon and Suneva combine to form $511M aesthetics business</title>
      <description>
        <![CDATA[Viveon Health Acquisition Corp. (VHAQ) reported a merger deal with regenerative aesthetics company Suneva Medical Inc. According to the terms of the deal, the special purpose acquisition company (SPAC), will issue 25 million shares and up to 12 million earnout shares to Suneva shareholders. The pro forma equity valuation of the companies is expected to be approximately $511 million, with the merger slated for completion in the first half of 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515119</guid>
      <pubDate>Thu, 13 Jan 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515119-viveon-and-suneva-combine-to-form-511m-aesthetics-business</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/SPAC-ticker-illustration.webp?t=1619724662" type="image/png" medium="image" fileSize="641269">
        <media:title type="plain">SPAC ticker illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Integra comes up short at FDA advisory for Surgimend for breast reconstruction</title>
      <description>
        <![CDATA[Despite that the device has been available for more than a decade under the 510(k) program, an FDA advisory committee voted narrowly that the benefits of the Surgimend device for breast reconstruction do not outweigh the risks. Another interesting feature of the application is that the pivotal study was based on real-world evidence (RWE), but while the FDA had direct access to the data, Integra Lifesciences Holdings Corp. did not, thus raising questions about whether RWE is necessarily useful for class III device premarket applications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512720</guid>
      <pubDate>Mon, 25 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512720-integra-comes-up-short-at-fda-advisory-for-surgimend-for-breast-reconstruction</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/10-25-Integra-Surgimend-mp.webp?t=1635199230" type="image/png" medium="image" fileSize="260883">
        <media:title type="plain">Image of gloved hands holding Surgimend product</media:title>
        <media:description type="plain">Surgimend is a collagen matrix for soft tissue reconstruction, featuring a highly macroporous design. Credit: Integra Lifesciences Holdings Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA recommends vision check before applying dermal fillers</title>
      <description>
        <![CDATA[The use of dermal fillers has spiked in recent years for a number of reasons, but so have the associated adverse events. An FDA advisory committee made several associated recommendations, including that a patient&rsquo;s vision be prospectively evaluated prior to any peri-ocular treatment with fillers, but this could be a simple count-the-fingers check, something that should not appreciably increase procedure times or affect the volume of procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505202</guid>
      <pubDate>Thu, 25 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505202-fda-recommends-vision-check-before-applying-dermal-fillers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-icons.webp?t=1588870105" type="image/png" medium="image" fileSize="458141">
        <media:title type="plain">FDA icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Bellaseno completes phase I trial of its Senella soft tissue reconstruction scaffold</title>
      <description>
        <![CDATA[PARIS &ndash; Bellaseno GmbH recently completed a phase I trial of its Senella absorbable soft tissue reconstruction scaffold on an Australian patient with congenital pectus excavatum. </em>]]>
      </description>
      <guid>http://www.bioworld.com/articles/496843</guid>
      <pubDate>Wed, 19 Aug 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496843-bellaseno-completes-phase-i-trial-of-its-senella-soft-tissue-reconstruction-scaffold</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-18-Bellaseno-Senella.webp?t=1597875002" type="image/png" medium="image" fileSize="232871">
        <media:title type="plain">Senella</media:title>
        <media:description type="plain">Senella absorbable soft tissue reconstruction scaffold. Credit: Bellaseno GmbH</media:description>
      </media:content>
    </item>
    <item>
      <title>Lifesprout scoops up $28.5M in series A</title>
      <description>
        <![CDATA[Baltimore-based Lifesprout Inc., a Johns Hopkins University startup, said it has closed a $28.5 million series A financing. It is planning to use the proceeds to support clinical development of therapeutic products from its Regenerative Matrix platform. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/434696</guid>
      <pubDate>Tue, 28 Apr 2020 12:45:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/434696-lifesprout-scoops-up-285m-in-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-pig-bank.webp?t=1588782533" type="image/png" medium="image" fileSize="419191">
        <media:title type="plain">Dollar sign in piggy bank</media:title>
      </media:content>
    </item>
    <item>
      <title>Lifesprout scoops up $28.5M in series A</title>
      <description>
        <![CDATA[Baltimore-based Lifesprout Inc., a Johns Hopkins University startup, said it has closed a $28.5 million series A financing. It is planning to use the proceeds to support clinical development of therapeutic products from its Regenerative Matrix platform. Redmile Group LLC led the round, with new institutional investors Nexus Management LP, Emerald Development Managers LP, and the Abell Foundation also joining.]]>
      </description>
      <guid>http://www.bioworld.com/articles/434680</guid>
      <pubDate>Mon, 27 Apr 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/434680-lifesprout-scoops-up-285m-in-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-pig-bank.webp?t=1588782533" type="image/png" medium="image" fileSize="419191">
        <media:title type="plain">Dollar sign in piggy bank</media:title>
      </media:content>
    </item>
    <item>
      <title>Soliton sees positive data from study of fibrotic scars</title>
      <description>
        <![CDATA[Soliton Inc., of Houston, unveiled positive proof-of-concept (POC) study results out to 12 weeks using its Rapid Acoustic Pulse (RAP) device for the treatment of fibrotic scars. Overall, the treatment of fibrotic scars using the device proved safe and tolerable during this POC study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432933</guid>
      <pubDate>Fri, 07 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432933-soliton-sees-positive-data-from-study-of-fibrotic-scars</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-7-Soliton-RAP.webp?t=1581113017" type="image/png" medium="image" fileSize="353245">
        <media:title type="plain">2-7-Soliton-RAP.png</media:title>
        <media:description type="plain">Industrial design renderings of the Rapid Acoustic Pulse
(RAP) device. Credit: Soliton Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sebacia names CEO, picks up Sienna assets</title>
      <description>
        <![CDATA[Duluth, Ga.-based Sebacia Inc., which is focused on dermatology and aesthetics, has introduced its new CEO and reported the acquisition of all assets related to Sienna Biopharmaceuticals Inc.&#39;s silver photoparticle technology, which is being reviewed by the FDA for light hair removal.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432334</guid>
      <pubDate>Fri, 10 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432334-sebacia-names-ceo-picks-up-sienna-assets</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-10-sebacia.webp?t=1578695123" type="image/png" medium="image" fileSize="692163">
        <media:title type="plain">1-10-sebacia.png</media:title>
        <media:description type="plain">Sebacia product family. Credit: Sebacia Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Establishment Labs eyes the Japanese market</title>
      <description>
        <![CDATA[Establishment Labs SA, from the Virgin Islands and with main manufacturing and marketing operations in Alajuela, Costa Rica, where it was founded, is entering the Japanese market with what it says is a revolutionary breast implant solution, starting this month.]]>
      </description>
      <guid>http://www.bioworld.com/articles/431922</guid>
      <pubDate>Thu, 19 Dec 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431922-establishment-labs-eyes-the-japanese-market</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/asia-japan-flag.webp?t=1588615539" type="image/png" medium="image" fileSize="316810">
        <media:title type="plain">Japanese flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Hologic to sell off 'underperforming' Cynosure, will focus on tuck-ins</title>
      <description>
        <![CDATA[Roughly two and half years after it picked up Cynosure, Hologic Inc., of Marlborough, Mass., has reported its intention to sell it to private equity firm Clayton, Dubilier &amp; Rice (CD&amp;R) for a total purchase price of $205 million in cash, subject to certain closing adjustments. The company expects net cash proceeds of about $138 million. CD&amp;R Partner Derek Strum expressed enthusiasm about the deal, noting that his firm expects &ldquo;to continue to invest behind the company&#39;s strong brand and large global installed base to accelerate growth via expanded sales &amp; marketing efforts and bring new products and technologies to market[.]&rdquo;]]>
      </description>
      <guid>http://www.bioworld.com/articles/431275</guid>
      <pubDate>Wed, 20 Nov 2019 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431275-hologic-to-sell-off-underperforming-cynosure-will-focus-on-tuck-ins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/divest-sell-pie.webp?t=1588276953" type="image/png" medium="image" fileSize="246044">
        <media:title type="plain">Serving piece of pie chart</media:title>
      </media:content>
    </item>
  </channel>
</rss>
